
Opus Genetics, Inc. — Investor Relations & Filings
Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company that develops gene therapies to treat inherited retinal diseases (IRDs) and other retinal disorders. The company focuses on advancing treatments that address genetic mutations causing vision loss. Its pipeline targets conditions such as Leber congenital amaurosis (LCA), bestrophinopathy (Best disease), and retinitis pigmentosa (RP). The company's primary mission is to restore vision and prevent blindness by creating an efficient path to bring new therapies to the clinic for patients with inherited blinding conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Opus Genetics, Inc. (0001228627) (Filer) | 2026-05-12 | English | |
| 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-05-12 | English | |
| 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-24 | English | |
| 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-22 | English | |
| 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-07 | English | |
| 4 - Opus Genetics, Inc. (0001228627) (Issuer) | 2026-03-18 | English |
Browse filings by year
24 years- 2026 26 filings
- 2025 101 filings
- 2024 65 filings
- 2023 56 filings
- 2022 53 filings
- 2021 50 filings
- 2020 77 filings
- 2019 50 filings
- 2018 49 filings
- 2017 38 filings
- 2016 32 filings
- 2015 32 filings
- 2014 40 filings
- 2013 29 filings
- 2012 25 filings
- 2011 34 filings
- 2010 30 filings
- 2009 41 filings
- 2008 29 filings
- 2007 27 filings
- 2006 24 filings
- 2005 50 filings
- 2004 16 filings
- 2003 6 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339306 | 10-Q - Opus Genetics, Inc. (0001228627) (Filer) | 2026-05-12 | English | ||
| 45232622 | 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-05-12 | English | ||
| 36294315 | 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-24 | English | ||
| 35205472 | 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-22 | English | ||
| 33703027 | 8-K - Opus Genetics, Inc. (0001228627) (Filer) | 2026-04-07 | English | ||
| 32979245 | 4 - Opus Genetics, Inc. (0001228627) (Issuer) | 2026-03-18 | English | ||
| 32979139 | 4 - Opus Genetics, Inc. (0001228627) (Issuer) | 2026-03-18 | English | ||
| 32889041 | 8-K - OPUS GENETICS, INC. (0001228627) (Filer) | 2026-02-19 | English | ||
| 32889040 | 4 - OPUS GENETICS, INC. (0001228627) (Filer) | 2026-02-17 | English | ||
| 28479870 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 28480001 | 4 Filing | 2026-01-26 | English | ||
| 28479961 | 4 Filing | 2026-01-26 | English | ||
| 28479923 | 4 Filing | 2026-01-26 | English | ||
| 28479847 | 4 Filing | 2026-01-26 | English | ||
| 28479839 | 4 Filing | 2026-01-26 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Bharat Parenterals Limited
Global manufacturer of WHO-GMP compliant medicinal formulat…
|
541096 | IN | Manufacturing |
|
Bicara Therapeutics Inc.
Clinical-stage biopharma developing dual-action biologics f…
|
BCAX | US | Manufacturing |
|
BICYCLE THERAPEUTICS PLC
Clinical-stage biopharma developing a novel class of bicycl…
|
BCYC | GB | Manufacturing |
|
BIFIDO. Co. Ltd
Biotechnology firm developing human-derived Bifidobacterium…
|
238200 | KR | Manufacturing |
|
Binex Co., Ltd.
Biopharmaceutical firm with pharma manufacturing and biolog…
|
053030 | KR | Manufacturing |
|
BioAge Labs, Inc.
A clinical-stage biotech developing therapies for metabolic…
|
BIOA | US | Manufacturing |
|
Bioasis Technologies Inc.
Developing the xB3 platform to deliver therapeutics across …
|
BIOAF | CA | Manufacturing |
|
BioAtla, Inc.
Develops antibody-based therapeutics activated within the t…
|
BCAB | US | Manufacturing |
|
BIOBIJOU Co., Ltd.
Develops and manufactures medical aesthetic products like H…
|
489460 | KR | Manufacturing |
|
BioCardia, Inc.
Develops cell-derived therapeutics for cardiovascular and p…
|
BCDA | US | Manufacturing |
Opus Genetics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34149/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34149 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34149 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34149 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34149}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Opus Genetics, Inc. (id: 34149)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.